A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. - O'DRISCOLL, LORRAINE (My University, 2007)
PUBLISHED